Abeona Therapeutics Stock
Abeona Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Vishwas Seshadri
- Employees
- 226
- Market cap
- $253 M
- IPO
- 19/09/1980
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for…
Abeona Therapeutics stock: price history
1D
-4.7%
1W
-10.3%
1M
-17.5%
6M
-19.5%
YTD
-15.9%
1Y
-19.0%
2Y
-32.1%
5Y
-80.5%
10Y
-97.8%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~15% weaker price swings than usual
Ask the agents about Abeona Therapeutics
Analyst assessment of Abeona Therapeutics
PRICE TARGET LOW
US$15.00
CONSENSUS
US$17.67
MEDIAN
US$17.00
PRICE TARGET HIGH
US$21.00
0
STRONG BUY
6
BUY
3
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 18/09/2026
Abeona Therapeutics stock metrics
P/E
-3.9
P/B
1.97
EV/EBITDA
-3.04
RETURN ON EQUITY
-15.8%
NET MARGIN
-177.4%
DEBT/EQUITY
0.16
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.4%
FLOAT SHARES
36,851,668
AVG. DAILY VOLUME (30D)
1,427,597
Insider transactions (SEC)
Seshadri Vishwas
Vazzano Joseph Walter
O'Malley Brendan M.
Vasanthavada Madhav
Alvino Mark
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Abeona Therapeutics stock
What does Abeona Therapeutics do?
Abeona Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Vishwas Seshadri, the company employs around 226 people.
The IPO was on 19/09/1980; the stock trades on NASDAQ under the ticker ABEO.
What do analysts say about Abeona Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 18/09/2026).
The average price target is US$17.67, ranging from US$15.00 to US$21.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does Abeona Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -15% stronger than usual.
Does Abeona Therapeutics pay a dividend?
Yes. The last dividend was US$0.59 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Abeona Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Abeona Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Abeona Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.